Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-55

You are on a virtual ignore (not an actual one - I've seen dozen of times how you mock those who've actually placed you on ignore, knowing you are safe from reprisal)


Barman, that was then, this is now. Sector was thankfully gone. I am not Sector. Just a CYP (and MSB) shareholder who dared to try to discuss, let me see now, what was it again, oh yes:



....but then got drawn into the usual anti-CYP acrimony despite being a positive poster on MSB for years.

And to politely answer your question (loosely), yes trying to predict opaque futures events, acknowledging a broad range of possibilities - who have us would have predicted 0 for 4 in MSB's near future in August 2020 - I am very much of the opinion both CYP and to a lesser degree MSB are very much unreflective of the forward value of most likely (probability adjusted) future events and earnings. And these srGVHD results from CYP just tied its future value a little more to a potential win in the near future by MSB with the FDA (even my main antagonist will not disagree that is likely) that in turn will very much raise the value of CYP's IP, trials and early business foundations, that Sumitomo only 4 years ago tried to pay $200 million to own, when less progressed, that now trades little above its cash on hand.